Company

MEDINNO Inc.

MEDINNO develops stem cell therapies for brain diseases and other conditions.

About

MEDINNO develops cell therapies using mesenchymal stem cells derived from umbilical cords. Its HIEstem product targets conditions including hypoxic ischemic encephalopathy and intraventricular hemorrhage. Founded in 2018, the company is based in Seoul, South Korea. It raised KRW 11 billion in pre-series C funding led by BNH Investment in October 2023.

4Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in